Articles producció científica> Medicina i Cirurgia

Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper fromthe Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

  • Datos identificativos

    Identificador: imarina:9282518
    Autores:
    Cuchel MBruckert EGinsberg HNRaal FJSantos RDHegele RAKuivenhoven JANordestgaard BGDescamps OSSteinhagen-Thiessen ETybjærg-Hansen AWatts GFAverna MBoileau CBorén JCatapano ALDefesche JCHovingh GKHumphries SEKovanen PTMasana LPajukanta PParhofer KGRay KKStalenhoef AFHStroes ETaskinen M-RWiegman AWiklund OChapman MJ
    Resumen:
    Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH. Methods and results: Early diagnosis ofHoFHand prompt initiation of diet and lipid-lowering therapy are critical. Genetic testing may provide a definitive diagnosis, but if unavailable, markedly elevated LDL-C levels together with cutaneous or tendon xanthomas before 10 years, or untreated elevated LDL-C levels consistent with heterozygous FH in both parents, are suggestive of HoFH.We recommend that patients with suspected HoFH are promptly referred to specialist centres for a comprehensiveACVDevaluation and clinical management. Lifestyle intervention and maximal statin therapy are the mainstays of treatment, ideally started in the first year of life or at an initial diagnosis, often with ezetimibe and other lipid-modifying therapy. As patients rarely achieve LDL-C targets, adjunctive lipoprotein apheresis is recommended where available, preferably started by age 5 and no later than 8 years. The number of therapeutic approaches has increased following approval of lomitapide and mipomersen for HoFH. Given the severity of ACVD, we recommend regular follow-up, including Doppler echocardiographic evaluation of the heart and aorta annually, stress tes
  • Otros:

    Autor según el artículo: Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AFH; Stroes E; Taskinen M-R; Wiegman A; Wiklund O; Chapman MJ
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Masana Marín, Luis
    Palabras clave: Xanthomatosis Xanthoma Triglyceride transfer protein Tendon xanthoma Surgical approach Statins Sitosterolemia Review Procedures Priority journal Practice guidelines as topic Practice guideline Plasma-cholesterol Phenotypic variation Phenotypic heterogeneity Phenotype Pedigree Mutation Monoclonal-antibody Mipomersen Low density lipoprotein cholesterol Lomitapide Liver-transplantation Liver transplantation Lipoprotein apheresis Lipid metabolism Lifestyle modification Ldl-apheresis In vivo study In vitro study Hypocholesterolemic agent Hyperlipoproteinemia type ii Hydroxymethylglutaryl coenzyme a reductase inhibitor Humans Human Homozygous familial hypercholesterolemia Homozygous familial hypercholesterolaemia Homozygote High risk patient Heart Health care facility Genetics Genetic variability Genetic screening Genetic heterogeneity Gene frequency Follow up Family history Familial hypercholesterolemia Ezetimibe Exercise test Early diagnosis Doppler echocardiography Disease severity Differential diagnosis Diet Diagnosis, differential Diagnosis Density-lipoprotein cholesterol Cutaneous xanthoma Coronary-heart-disease Cornea curvature Controlled-trial Consensus development Computer assisted tomography Computed tomographic angiography Cholesterol, ldl Cholesterol blood level Cardiovascular magnetic resonance Cardiovascular diseases Cardiovascular disease Blood component removal Atherosclerotic cardiovascular disease Atherosclerosis Arcus senilis Apolipoprotein-b Apheresis Aortic-stenosis Aorta Antilipemic agent Anticholesteremic agents phenotypic heterogeneity mipomersen lomitapide lipoprotein apheresis homozygous familial hypercholesterolaemia genetics ezetimibe diagnosis
    Resumen: Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH. Methods and results: Early diagnosis ofHoFHand prompt initiation of diet and lipid-lowering therapy are critical. Genetic testing may provide a definitive diagnosis, but if unavailable, markedly elevated LDL-C levels together with cutaneous or tendon xanthomas before 10 years, or untreated elevated LDL-C levels consistent with heterozygous FH in both parents, are suggestive of HoFH.We recommend that patients with suspected HoFH are promptly referred to specialist centres for a comprehensiveACVDevaluation and clinical management. Lifestyle intervention and maximal statin therapy are the mainstays of treatment, ideally started in the first year of life or at an initial diagnosis, often with ezetimibe and other lipid-modifying therapy. As patients rarely achieve LDL-C targets, adjunctive lipoprotein apheresis is recommended where available, preferably started by age 5 and no later than 8 years. The number of therapeutic approaches has increased following approval of lomitapide and mipomersen for HoFH. Given the severity of ACVD, we recommend regular follow-up, including Doppler echocardiographic evaluation of the heart and aorta annually, stress testing and, if available, computed tomography coronary angiography every 5 years, or less if deemed necessary. Conclusion: This EAS Consensus Panel highlights the need for early identification of HoFH patients, prompt referral to specialized centres, and early initiation of appropriate treatment. These recommendations offer guidance for a wide spectrum of clinicians who are often the first to identify patients with suspected HoFH. © The Author 2014.
    Áreas temáticas: Saúde coletiva Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Educação física Direito Ciências biológicas ii Ciências biológicas i Cardiology and cardiovascular medicine Cardiac & cardiovascular systems
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: luis.masana@urv.cat
    Identificador del autor: 0000-0002-0789-4954
    Fecha de alta del registro: 2024-09-07
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://academic.oup.com/eurheartj/article/35/32/2146/2481389?login=false
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: European Heart Journal. 35 (32): 2146-2157
    Referencia de l'ítem segons les normes APA: Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen (2015). Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper fromthe Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 35(32), 2146-2157. DOI: 10.1093/eurheartj/ehu274
    DOI del artículo: 10.1093/eurheartj/ehu274
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2015
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Cardiac & Cardiovascular Systems,Cardiology and Cardiovascular Medicine
    Xanthomatosis
    Xanthoma
    Triglyceride transfer protein
    Tendon xanthoma
    Surgical approach
    Statins
    Sitosterolemia
    Review
    Procedures
    Priority journal
    Practice guidelines as topic
    Practice guideline
    Plasma-cholesterol
    Phenotypic variation
    Phenotypic heterogeneity
    Phenotype
    Pedigree
    Mutation
    Monoclonal-antibody
    Mipomersen
    Low density lipoprotein cholesterol
    Lomitapide
    Liver-transplantation
    Liver transplantation
    Lipoprotein apheresis
    Lipid metabolism
    Lifestyle modification
    Ldl-apheresis
    In vivo study
    In vitro study
    Hypocholesterolemic agent
    Hyperlipoproteinemia type ii
    Hydroxymethylglutaryl coenzyme a reductase inhibitor
    Humans
    Human
    Homozygous familial hypercholesterolemia
    Homozygous familial hypercholesterolaemia
    Homozygote
    High risk patient
    Heart
    Health care facility
    Genetics
    Genetic variability
    Genetic screening
    Genetic heterogeneity
    Gene frequency
    Follow up
    Family history
    Familial hypercholesterolemia
    Ezetimibe
    Exercise test
    Early diagnosis
    Doppler echocardiography
    Disease severity
    Differential diagnosis
    Diet
    Diagnosis, differential
    Diagnosis
    Density-lipoprotein cholesterol
    Cutaneous xanthoma
    Coronary-heart-disease
    Cornea curvature
    Controlled-trial
    Consensus development
    Computer assisted tomography
    Computed tomographic angiography
    Cholesterol, ldl
    Cholesterol blood level
    Cardiovascular magnetic resonance
    Cardiovascular diseases
    Cardiovascular disease
    Blood component removal
    Atherosclerotic cardiovascular disease
    Atherosclerosis
    Arcus senilis
    Apolipoprotein-b
    Apheresis
    Aortic-stenosis
    Aorta
    Antilipemic agent
    Anticholesteremic agents
    phenotypic heterogeneity
    mipomersen
    lomitapide
    lipoprotein apheresis
    homozygous familial hypercholesterolaemia
    genetics
    ezetimibe
    diagnosis
    Saúde coletiva
    Nutrição
    Me
  • Documentos:

  • Cerca a google

    Search to google scholar